▴ Parecoxib (parecoxib sodium) is an injectable prodrug of valdecoxib, which is a potent and selective inhibitor of cyclo-oxygenase-2.
▴ Intravenous (TV) or intramuscular (IM) parecoxib ≥20mg has analgesic activity superior to that of placebo and similar to that of IV or IM ketorolac 30 or 60mg in well controlled trials in patients with postoperative dental pain (n = 304 to 457).
▴ In a well controlled trial (n = 202), IV parecoxib 20 or 40mg showed analgesic activity greater than that of placebo and IV morphine 4mg and similar to that of IV ketorolac 30mg following gynaecological surgery.
▴ Following orthopaedic surgery, the analgesic activity of IV parecoxib 20 or 40mg was similar to that of IV ketorolac 30mg and superior to that of IV morphine 4mg or placebo in well controlled trials (n = 175 and 208).
▴ IV parecoxib (40mg twice daily for 7 days) produced significantly fewer gastrointestinal erosions and/or ulcers than ketorolac (15mg 4 times a day for 5 days) in healthy volunteers in a well controlled trial; effects on upper gastrointestinal mucosa were similar for parecoxib and placebo.
▴ Parecoxib is well tolerated after dental, gynaecological or orthopaedic surgery. The most common adverse events irrespective of treatment (parecoxib, ketorolac or placebo) after dental surgery were nausea, alveolar osteitis, dizziness and headache.
▴ Nausea, abdominal pain, headache, abdominal fullness, dizziness, back pain, fever, hypoactive bowel sounds, vomiting, tachycardia, somnolence, abnormal breath sounds and pruritus occurred in ≥10% of parecoxib recipients after gynaecological surgery. Similar results were seen in placebo recipients.
- 4.Bolten WW. Scientific rationale for specific inhibition of COX- 2. J Rheumatol 1998 May 25; 25 Suppl. 51: 2–7Google Scholar
- 5.Needleman P, Isakson PC. The discovery and function of COX- 2.J Rheumatol 1997; 24 Suppl. 49: 6–8Google Scholar
- 7.Mosby. Mosby’s GenRx Update 3. Ketorolac Tromethamine 2001Google Scholar
- 9.Hubbard RC, Kuss ME, Daniels SE, et al. Parecoxib, a new parenteral COX-2 specific inhibitor with an enhanced analgesic profile. WWPC; 2000 Jul; San Francisco, CAGoogle Scholar
- 10.Daniels SE, Kuss M, Mehlisch DR, et al. Pharmacokinetic and efficacy evaluation of intravenous parecoxib in a postsurgical dental pain model [poster]. ASCPT; 2000 Mar; Los Angeles (CA)Google Scholar
- 11.Mehlisch D, Kuss M, Bauman A, et al. Onset and duration of analgesia of intramuscular doses of paracoxib, and ne parenteral COX-2 inhibitor, in postoperative dental pain [poster]. APS; 1999 Nov; Ft Lauderdale (FL)Google Scholar
- 12.Langland F, Turpin M, Waller P, et al. A comparative analgesic efficacy study of parecoxib, a new COX-2 specific inhibitor, in post-gynecological surgery patients [poster no. 814]. Presented at the 19th Annual Scientific Meeting of the American Pain Society; 2000 NovGoogle Scholar
- 14.Kenaan CA, Bikhazi GB, Deepika K, et al. Analgesic activity and safety of parecoxib in post-surgical patients: an interim report [abstract no. 257]. Anesth Analg 2001; 92 Suppl.: S257Google Scholar
- 15.Malan TP, Marsh G, Grossman E, et al. Evaluation of the opiod-sparing effectiveness of parecoxib sodium, a new COX-2 specific inhibitor, in the management of postoperative pain following total hip arthroplasty [abstract no. 774]. J Pain Symptom Manage 2001 Apr; 2 Suppl. 1: 38Google Scholar
- 16.Rasmussen GL, Stecker K, Hogue CW, et al. A comparative analgesic efficacy study of parecoxib sodium, a new injectable COX-2 inhibitor, in post-orthopedic surgery patients [abstract no. 776]. J Pain Symptom Manage 2001; 2 Suppl. 1: 39Google Scholar
- 18.Hubbard ME, Kuss D, LeComte S, et al. An endoscopic study of the gastroduodenal effects of parecoxib sodium, an injectable COX-2 inhibitor in the elderly. Dig Dis Week; 2000 May 21–24; San Diego (CA)Google Scholar
- 19.Noveck RJ, Kuss ME, Qian J, et al. Parecoxib sodium, an injectable COX-2 specific inhibitor, does not affect aspirin-mediated platelet function [abstract no. 19]. Regional Anesthesia and Pain Medicine 2001 Mar-Apr; 26 (2 Suppl.): ASRA 26th Annual Meeting: 2001 May 10–13: Vancouver; W.B Saunders Company, 2001: 19Google Scholar
- 20.Noveck RJ, Kuss ME, Qian J, et al. Parecoxib sodium, an injectable COX-2 specific inhibitor, does not affect heparinregulated blood coagulation parameters [abstract no. 20]. Regional Anesthesia and Pain Medicine 2001 Mar–Apr; 26 (2 Suppl.): ASRA 26th Annual Meeting: 2001 May 10–13; Vancouver; W.B. Saunders Company, 2001: 20Google Scholar
- 21.Grossman E, Hubbard R, Laurent A, et al. A safety and pharmacokinetic study of analgesic doses of parecoxib sodium, a new COX-2 specific inhibitor, in healthy subjects [poster no. 653]. Presented at the 19th Annual Scientific Meeting of the American Pain Society; 2000 NovGoogle Scholar
- 22.Karim A, Laurent A, Kuss M, et al. Single dose tolerability and pharmacokinetics of parecoxib sodium, a COX-2 specific inhibitor, following intravenous administration [abstract no. A-944]. Annual Meeting of the American Society of Anesthesiologists, 2000Google Scholar
- 23.Ibrahim A, Karim A, Feldman J, et al. Effects of parecoxib, a parenteral COX-2 specific inhibitor, on the disposition of midazolam [abstract no. 529]. Annual Meeting of the American Society of Anesthesiologists, 2000Google Scholar
- 24.Hubbard R, Kuss M, Talwalker S, et al. Evaluation of parecoxib, a new injectable cyclooxygenase-2-specific inhibitor, for the treatment of pain [abstract no. 266]. Ann Emerg Med 2000 Oct; 36 Suppl.: S69Google Scholar
- 25.Mehlisch D, Kuss M, Bauman A, et al. Correlation of pharmacokinetics (PK) with onset and duration of analgesia of intramuscular doses of parecoxib, in postoperative dental pain [poster no. PIII-7]. ASCPT; 2000 Mar; Los Angeles (CA)Google Scholar
- 26.Ibrahim A, Park S, Feldman J, et al. Effects of parecoxib, a parenteral COX-2 specific inhibitor, on the disposition of propofol [abstract no. 530]. Anesthesiology 2000 Sep; 93 (3A Suppl.): 56Google Scholar